Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years

NCT00266552 is registered in ClinicalTrials.gov with Janssen Pharmaceutica N.V., Belgium as lead sponsor.

NCT NCT00266552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00266552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety And Efficacy Of Risperidone Versus Placebo In Conduct Disorder and Other Disruptive Behavior Disorders In Mild, Moderate And Borderline Mentally Retarded Children Aged 5 To 12 Years
Lead sponsor
Janssen Pharmaceutica N.V., Belgium
Phase
Phase 3
Overall status
Completed
Start date
Not reported
Completion date
October 31, 1998
Enrollment
118 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

conduct disorder, disruptive behavior disorder, oppositional defiant disorder